Suvi-Katri Leivonen

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 14

Top Venues

PloS one

Cancers

Leukemia

European journal of haematology

University of Oslo

Turun Yliopisto (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Oslo Jan 01 2012 - Jan 12 2014

Norway

Post-doctoral fellow

Education History

Turun Yliopisto

Finland

PHD

Publications

Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Lisa Svartdal Normann, Mads Haugland Haugen, Vesa Hongisto, Miriam Ragle Aure, Suvi-Katri Leivonen, Vessela N Kristensen, Andliena Tahiri, Olav Engebraaten, Kristine Kleivi Sahlberg, Gunhild Mari Mælandsmo
High-throughput screen in vitro identifies dasatinib as a candidate for combinatorial treatment with HER2-targeting drugs in breast cancer. PloS one 18 (1) (2023)
Kristiina Karihtala, Suvi-Katri Leivonen, Marja-Liisa Karjalainen-Lindsberg, Fong Chun Chan, Christian Steidl, Teijo Pellinen, Sirpa Leppa
Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients. Blood advances 6 (6) (2022)
Heli Vajavaara, Suvi-Katri Leivonen, Judit Meszaros Jørgensen, Harald Holte, Sirpa Leppa
Low lymphocyte-to-monocyte ratio predicts poor outcome in high-risk aggressive large B-cell lymphoma. EJHaem 3 (3) (2022)
Matias Autio, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Teijo Pellinen, Sirpa Leppa
Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (4) (2022)
Marjukka Pollari, Suvi-Katri Leivonen, Sirpa Leppa
Testicular Diffuse Large B-Cell Lymphoma-Clinical, Molecular, and Immunological Features. Cancers 13 (16) (2021)
Shay Ben-Elazar, Miriam Ragle Aure, Kristin Jonsdottir, Suvi-Katri Leivonen, Vessela N Kristensen, Emilius A M Janssen, Kristine Kleivi Sahlberg, Ole Christian Lingjærde, Zohar Yakhini
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer. PLoS computational biology 17 (2) (2021)
Heli Vajavaara, Julie Bondgaard Mortensen, Suvi-Katri Leivonen, Ida Monrad Hansen, Maja Ludvigsen, Harald Holte, Judit Jørgensen, Mette Bjerre, Francesco d'Amore, Sirpa Leppa
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma. Cancers 13 (3) (2021)
Marjukka Pollari, Teijo Pellinen, Marja-Liisa Karjalainen-Lindsberg, Pirkko-Liisa Kellokumpu-Lehtinen, Suvi-Katri Leivonen, Sirpa Leppa
Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma. European journal of haematology 105 (6) (2020)
Kristiina Karihtala, Suvi-Katri Leivonen, Oscar Brück, Marja-Liisa Karjalainen-Lindsberg, Mohamed El Missiry, Teijo Pellinen, Sirpa Leppa
Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma. Cancers 12 (4) (2020)
Amjad Alkodsi, Alejandra Cervera, Kaiyang Zhang, Riku Louhimo, Leo Meriranta, Annika Pasanen, Suvi-Katri Leivonen, Harald Holte, Sirpa Leppa, Rainer Lehtonen, Sampsa Hautaniemi
Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. Leukemia 33 (11) (2019)

Suvi-Katri Leivonen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Suvi-Katri Leivonen